Patents Assigned to Medical Research Council
-
Publication number: 20150224054Abstract: The present invention concerns nanoparticle formulations suitable for the delivery of one or more therapeutic agents, the formulations comprising: a cationic cholesterol derivative; a neutral phospholipid; cholesterol or a neutral cholesterol derivative; and a saturated fatty acid, PEGylated neutral derivative of phosphatidylethanolamine or phosphatidylcholine.Type: ApplicationFiled: August 28, 2013Publication date: August 13, 2015Applicants: IMPERIAL INNOVATIONS LTD, MEDICAL RESEARCH COUNCILInventors: Jimmy Bell, Elizabeth Louise Thomas, Leigh Brody, Meliz Sahuri Arisoylu, Andrew Miller, Gary Frost
-
Patent number: 9096835Abstract: The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described.Type: GrantFiled: June 19, 2012Date of Patent: August 4, 2015Assignee: Medical Research CouncilInventors: Philipp Holliger, Farid Ghadessy, Marc d'Abbadie
-
Patent number: 9089565Abstract: The invention relates to a method for alleviating the inhibition of neurite outgrowth from a neurone, wherein said neurone comprises a Nogo receptor, said method comprising contacting said neurone with a composition capable of causing phosphorylation of a Nogo receptor, wherein said composition comprises protein kinase A or casein kinase.Type: GrantFiled: March 5, 2010Date of Patent: July 28, 2015Assignee: MEDICAL RESEARCH COUNCILInventor: Yoshinori Takei
-
Patent number: 9084757Abstract: This invention relates to an osteogenic device for the de novo induction of bone formation in a mammal. The device contains at least one transforming growth factor-?3 isoform and a retention matrix. The device is introduced by direct injection or surgical implantation into an area where de novo bone formation is desired and, once implanted, the retention matrix acts to retain the TGF-?3 isoform at its place of introduction and forms a scaffold for generated bone, the induction of which is promoted by the TGF-?3 isoform. The device may be used to induce bone growth where bone has been debrided in a surgical procedure and it may also be used to transform neoplastic primary and/or metastatic secondary masses into bone thus facilitating surgical debridement thereof.Type: GrantFiled: May 3, 2012Date of Patent: July 21, 2015Assignees: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, RIPAMONTI, UGO BONE RESEARCH LABORATORY, FACULTY OF HEALTH SCIENCES, MEDICAL RESEARCH COUNCIL OF SOUTH AFRICAInventor: Ugo Ripamonti
-
Patent number: 9074202Abstract: The invention provides a method of modulating Wnt signalling comprising modulating Trabid activity. Preferably modulating Trabid activity comprises inhibiting; Trabid activity. The invention also provides a method of reducing TCF transcription, said method comprising reducing Trabid activity. A method for identifying a-modulator of Trabid said method comprising; providing a Trabid substrate comprising a detectable moiety coupled to a tag moiety by ubiquitin; immobilizing first and second portions of said substrate; adding a candidate modulator to the first said portion; contacting first and second portions with Trabid; incubating to allow Trabid action, assaying cleavage of ubiquitin by separation of tag from detectable moiety, wherein separation of an amount of detectable moiety from said first portion which is different from the amount of detectable moiety separated from said second portion identifies said candidate as a modulator of Trabid.Type: GrantFiled: May 21, 2007Date of Patent: July 7, 2015Assignee: MEDICAL RESEARCH COUNCILInventors: Mariann Bienz, Felix Randow, Hoanh Tran, Thomas Schwarz-Romond
-
Publication number: 20150168409Abstract: Some embodiments are related to a method for determining if a subject has an increased likelihood of high grade dysplasia (HGD) or esophagal adenocarcinoma (EC). An exemplary method can include providing a sample from an AFI patch of the subject's esophagus, assaying the sample for (i) aneuploidy, and (ii) abnormal p53, and (iii) abnormal Cyclin A, wherein if the sample shows the presence of at least two of (i), (ii) and (iii), then the subject is determined as having an increased likelihood of high grade dysplasia (HGD) or esophagal adenocarcinoma (EC). The invention also relates to certain methods of medical treatment.Type: ApplicationFiled: May 17, 2013Publication date: June 18, 2015Applicants: The University of Cambridge, Medical Research CouncilInventors: Massimiliano Di Pietro, Rebecca Fitzgerald, Xinxue Liu
-
Publication number: 20150160220Abstract: In some embodiments, a method for aiding prediction of the likelihood of progression from Barrett's esophagus to high grade dysplasia or esophageal adenocarcinoma in a subject, is disclosed. The method can include (a) providing an oesophagal sample from said subject (b) determining if said sample stains abnormally with Aspergillus oryzae lectin; (c) determining if there is a DNA content abnormality in said sample; and (d) determining if there is low grade dysplasia in said sample; wherein if (b) is abnormal and (c) is abnormal and low grade dysplasia is present, then an increased likelihood of progression is determined. The disclosed subject matter also relates to an apparatus, and to different uses of certain materials.Type: ApplicationFiled: May 16, 2013Publication date: June 11, 2015Applicant: Medical Research CouncilInventors: Rebecca Fitzgerald, Elizabeth Bird-Lieberman
-
Patent number: 9045505Abstract: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.Type: GrantFiled: March 26, 2010Date of Patent: June 2, 2015Assignees: University of Otago, Medical Research CouncilInventors: Robin Andrew James Smith, Michael Patrick Murphy
-
Patent number: 9029083Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: October 10, 2005Date of Patent: May 12, 2015Assignees: Medical Research Council, President and Fellows of Harvard CollegeInventors: Andrew David Griffiths, David Weitz, Darren Link, Keunho Ahn, Jerome Bibette
-
Patent number: 9028801Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.Type: GrantFiled: December 7, 2005Date of Patent: May 12, 2015Assignees: Electrophoretics Limited, Medical Research Council, University College LondonInventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
-
Publication number: 20150105265Abstract: In some embodiments, a method for aiding assessment of the likelihood of dysplasia or esophageal adenocarcinoma being present in a subject can include (a) providing an esophagal sample from said subject (b) determining the methylation status of (i) SLC22A18, (ii) PIGR, (iii) GJA12 and (iv) RIN2 in said sample wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophageal is determined. The invention also relates to apparatus for same.Type: ApplicationFiled: May 17, 2013Publication date: April 16, 2015Applicant: Medical Research CouncilInventors: Rebecca Fitzgerald, Muhammad Alvi, Xinxue Liu
-
Publication number: 20150004622Abstract: The present invention, relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods.Type: ApplicationFiled: February 7, 2014Publication date: January 1, 2015Applicant: Medical Research CouncilInventors: PIERRE LAO-SIRIEIX, REBECCA C. FITZGERALD
-
Patent number: 8916681Abstract: The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual. In addition, the invention provides methods of identifying and/or using antagonists of kisspeptin and/or the defined peptides, and pharmaceutical compositions thereof.Type: GrantFiled: October 8, 2008Date of Patent: December 23, 2014Assignee: Medical Research CouncilInventors: Robert Peter Millar, Antonia Kathryn Roseweir
-
Publication number: 20140342992Abstract: The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based theraputics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI.Type: ApplicationFiled: August 29, 2012Publication date: November 20, 2014Applicant: Medical Research CouncilInventors: Michael John Gait, Andrey Alexandrovich Arzumanov, Amer F. Saleh, Matthew J.A. Wood, Corinne Betts, Taeyoung Koo
-
Publication number: 20140322204Abstract: Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection.Type: ApplicationFiled: March 21, 2014Publication date: October 30, 2014Applicant: Medical Research CouncilInventors: Arvind PATEL, Jonathan Ball
-
Patent number: 8871444Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalizing genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: December 4, 2012Date of Patent: October 28, 2014Assignees: Medical Research Council, President and Fellows of Harvard CollegeInventors: Andrew David Griffiths, David A. Weitz, Darren R. Link, Keunho Ahn, Jerome Bibette
-
Patent number: 8865643Abstract: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.Type: GrantFiled: February 3, 2011Date of Patent: October 21, 2014Assignee: Medical Research CouncilInventors: Howard Clark, Palaniyar Nadesalingam, Kenneth B. Reld, Peter Strong
-
Publication number: 20140302582Abstract: The invention provides a chimeric E2 enzyme comprising a Ubc domain fused to a heterologous ubiquitin binding domain (UBD). The chimeric enzymes of the invention may be useful in producing elevated levels of free polyubiquitin.Type: ApplicationFiled: May 13, 2014Publication date: October 9, 2014Applicant: MEDICAL RESEARCH COUNCILInventors: David Komander, Anja Bremm
-
Patent number: 8852589Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: GrantFiled: October 17, 2013Date of Patent: October 7, 2014Assignee: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Publication number: 20140287528Abstract: The invention relates to A method of making a polypeptide comprising at least one N?-methyl-lysine at a specific site in said polypeptide, said method comprising (a) genetically directing the incorporation of R—N?-methyl-lysine into said polypeptide, wherein R comprises an auxiliary group; and (b) catalysing the removal of R from the polypeptide of (a). In particular the invention relates to such a method wherein genetically directing the incorporation of R—N?-methyl-lysine into said polypeptide comprises arranging for the translation of a RNA encoding said polypeptide, wherein said RNA comprises an amber codon, and wherein said translation is carried out in the presence of an amber tRNA charged with R—N?-methyl-lysine.Type: ApplicationFiled: October 8, 2013Publication date: September 25, 2014Applicant: MEDICAL RESEARCH COUNCILInventors: Jason Chin, Duy P. Nguyen